等待開盤 02-06 09:30:00 美东时间
+32.435
+10.80%
华盛资讯2月5日讯,Corpay, Inc.公布2025财年Q4业绩,公司Q4营收12.48亿美元,同比增长20.7%,归母净利润2.64亿美元,同比增长7.5%。
02-05 23:50
Morgan Stanley analyst James Faucette maintains Corpay (NYSE:CPAY) with a Overweight and raises the price target from $379 to $390.
02-05 21:39
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 基于Corpay业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **第四季度业绩表现:** - 营收达到12.48亿美元,同比增长21%,超出内部预期 - 有机营收增长11%,连续第三个季度实现该增长率 - 调整后每股收益6.04美元,同比增长13%(按恒定税率计算增长20%) - 现金EBITDA超过7亿美元 - 调整后EBITDA利润率为57.1% **全年2025年业绩表现:** - 全年营收45.28亿美元,同比增长14% - 有机营收增长10%(过去五年中有四年实现10%或以上有机增长) - 调整后每股收益21.38美元,同比增
02-05 12:21
Corpay (NYSE:CPAY) is looking for Q1 Adj EPS of $5.38-$5.52 vs $5.44 analyst estimate..
02-05 07:40
艾利科技涨12.83%;Symbotic, Inc. Class A涨11.41%;Corpay, Inc.涨9.39%
02-05 07:11
Corpay, Inc. (NYSE: CPAY), the corporate payments company, announced that it has signed a definitive agreement to sell PayByPhone, a mobile parking payments business, to Lightyear Capital.The transaction is not expected
02-04 22:05
Companies Reporting Before The Bell • Oaktree Specialty Lending (NASDAQ:OCSL) i...
02-04 19:11
今日重点评级关注:瑞穗:维持Syndax制药"跑赢大市"评级,目标价从410美元升至600美元;HC Wainwright & Co.:维持60 Degrees Pharmaceuticals, Inc."买入"评级,目标价从6美元升至24美元
01-28 10:59
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02